Christoph A. Schatz

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

Ningshu Liu, Bruce R. Rowley, Cathy Bull et al. · Molecular Cancer Therapeutics · 2013 · 256 citations

Medicine, Oncology, Pharmacology +15

Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

Sven Golfier, Charlotte Kopitz, Antje Kahnert et al. · Molecular Cancer Therapeutics · 2014 · 253 citations

Medicine, Oncology, Pharmacology +17

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

Antje M. Wengner, Gerhard Siemeister, Ulrich Lücking et al. · Molecular Cancer Therapeutics · 2019 · 210 citations

Medicine, Molecular Biology, Oncology +17

BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

Gerhard Siemeister, Ulrich Lücking, Antje M. Wengner et al. · Molecular Cancer Therapeutics · 2012 · 157 citations · Full text

Medicine, Oncology, Pharmacology +17

Exploratory Clinical Trial of (4 <i>S</i> )-4-(3-[18F]fluoropropyl)- <scp>l</scp> -glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Sora Baek, Chang‐Min Choi, Sei Hyun Ahn et al. · Clinical Cancer Research · 2012 · 132 citations · Full text

Medicine, Nuclear Medicine, Radiology +16